(NewsDirect)
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett joinsProactive’s Jonathan Jackson to discuss promising preclinicalfindings. Research indicated that combining bisantrene with decitabinegreatly enhances the destruction of cancer cells across a wide varietyof types, potentially expanding decitabine's use beyond bloodcancers to solid tumours. This combination could address cancersincluding those of the lung, prostate, pancreas, breast and head andneck. Decitabine, traditionally used for blood cancers likemyelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), hadnot been effective in treating solid tumours prior to these findings.The study, conducted at Oncolines B.V. in the Netherlands, involvedscreening the combination across 143 cancer cell lines from over 20human tissues, encompassing both solid and blood cancers. Resultsshowed a significant increase in cancer cell death, with 92% of thecell lines exhibiting improved outcomes. Tillett expressed optimismabout these findings, highlighting the potential for new treatmentavenues and the plan to initiate a clinical trial soon. Thisdevelopment suggests substantial interest for owners of marketedformulations of decitabine, including oral variants.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.